

# Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

## Covaris: E220evolution Focused ultrasonicator

RRID:SCR\_019817

Type: Tool

---

### Proper Citation

Covaris: E220evolution Focused ultrasonicator (RRID:SCR\_019817)

---

### Resource Information

**URL:** <https://covaris.com/products/afa-ultrasonication/e220evolution/>

**Proper Citation:** Covaris: E220evolution Focused ultrasonicator (RRID:SCR\_019817)

**Description:** Focused ultrasonicator that enables multi sample, batch preparation, capable of processing wide range of sample types and volumes.

**Resource Type:** instrument resource

**Keywords:** Covaris, Focused Ultrasonicator, Covaris, Instrument Equipment, USEDit,

**Availability:** Commercially available

**Specification URL:** [https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR\\_019817.pdf](https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_019817.pdf)

**Resource Name:** Covaris: E220evolution Focused ultrasonicator

**Resource ID:** SCR\_019817

**Alternate IDs:** Model\_Number\_E220\_Evolution

**Alternate URLs:** [https://www.covaris.com/wp/wp-content/uploads/resources\\_pdf/M020001.pdf](https://www.covaris.com/wp/wp-content/uploads/resources_pdf/M020001.pdf)

**Record Creation Time:** 20220129T080347+0000

**Record Last Update:** 20260801T190638+0000

---

### Ratings and Alerts

No rating or validation information has been found for Covaris: E220evolution Focused ultrasonicator.

No alerts have been found for Covaris: E220evolution Focused ultrasonicator.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. Cancer research, 85(11), 1978.

Van Laethem JL, et al. (2025) CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Cell reports. Medicine, 6(10), 102407.